Premium
Pregnancy‐Specific β‐1 Glycoprotein (SP‐1) in Normal and Abnormal Pregnancy
Author(s) -
Chapman M. G.,
Jones W. R.
Publication year - 1978
Publication title -
australian and new zealand journal of obstetrics and gynaecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.734
H-Index - 65
eISSN - 1479-828X
pISSN - 0004-8666
DOI - 10.1111/j.1479-828x.1978.tb00042.x
Subject(s) - human placental lactogen , pregnancy , gestation , radial immunodiffusion , glycoprotein , endocrinology , medicine , fetus , obstetrics , biology , placenta , antibody , immunology , biochemistry , genetics
Summary: Maternal serum levels of a pregnancy specific β‐1 glycoprotein (SP‐1) were measured by radial‐immunodiffusion in 369 normal pregnancies. Mean levels rose progressively to approximately 200 mg/l at 36 weeks of gestation followed by a plateau and a fall at term. The 95% confidence limits were established for SP‐1 by logarithmic correction of the positively skewed raw data and certain theoretical and practical advantages were demonstrated in the use of SP‐1 compared with human placental lactogen (HPL) measurement in the assessment of fetal‐placental growth and function. In a preliminary study of abnormal pregnancy states it was found that maternal serum SP‐1 assay may aid in the early detection of retarded intrauterine growth, and that it provides a better monitoring system than HPL in this condition. SP‐1 levels were normal in pregnancies complicated by hypertension without retarded intrauterine growth.